Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan)

[Guest guest]

Hepatology. 2010 Dec 14. doi: 10.1002/hep.24121. [Epub ahead of print]

Risk assessment of hepatitis B virus-related hepatocellular carcinoma

development using liver stiffness measurement (FibroScan)

Jung KS, Kim SU, Ahn SH, Park YN, Kim DY, Park JY, Chon CY, Choi EH, Han KH.

Department of Internal Medicine, Yonsei University College of Medicine, Seoul,

Korea.

Abstract

Liver stiffness measurement (LSM) using FibroScan accurately assesses the degree

of liver fibrosis and the risk of hepatocellular carcinoma (HCC) development in

patients with chronic hepatitis C. This study investigated the usefulness of LSM

as a predictor of HCC development in patients with chronic hepatitis B (CHB). A

total of 1,130 patients with non-biopsy-proven CHB who underwent LSM between May

2005 and December 2007 were enrolled in this prospective study. After LSM was

performed, patients attended regular follow-up as part of a surveillance program

for the detection of HCC. The mean age of the patients (767 men, 363 women) was

50.2 years, and the median LSM was 7.7 kPa. Six hundred seventy-two (59.5%)

patients received antiviral treatment before or after enrollment. During the

follow-up period (median, 30.7 months; range, 24.0-50.9 months), HCC developed

in 57 patients (2.0% per 1 person-year). The 1-, 2-, and 3-year cumulative

incidence rates of HCC were 0.80%, 3.26%, and 5.98%, respectively. On

multivariate analysis, together with old age, male sex, heavy alcohol

consumption (>80 g/day), serum albumin, and hepatitis B e antigen positivity,

patients with a higher LSM (>8 kPa) were at a significantly greater risk of HCC

development, with the following hazard ratios: 3.07 (95% confidence interval

[CI], 1.01-9.31; P = 0.047) for LSM 8.1-13 kPa; 4.68 (95% CI, 1.40-15.64; P =

0.012) for LSM 13.1-18 kPa; 5.55 (95% CI, 1.53-20.04; P = 0.009) for LSM 18.1-23

kPa; and 6.60 (95% CI, 1.83-23.84; P = 0.004) for LSM >23 kPa. Conclusion: Our

data suggest that LSM could be a useful predictor of HCC development in patients

with CHB.

(HEPATOLOGY 2011).

American Association for the Study of Liver Diseases.

PMID: 21319193 [PubMed - as supplied by publisher

[Guest guest]

Hepatology. 2010 Dec 14. doi: 10.1002/hep.24121. [Epub ahead of print]

Risk assessment of hepatitis B virus-related hepatocellular carcinoma

development using liver stiffness measurement (FibroScan)

Jung KS, Kim SU, Ahn SH, Park YN, Kim DY, Park JY, Chon CY, Choi EH, Han KH.

Department of Internal Medicine, Yonsei University College of Medicine, Seoul,

Korea.

Abstract

Liver stiffness measurement (LSM) using FibroScan accurately assesses the degree

of liver fibrosis and the risk of hepatocellular carcinoma (HCC) development in

patients with chronic hepatitis C. This study investigated the usefulness of LSM

as a predictor of HCC development in patients with chronic hepatitis B (CHB). A

total of 1,130 patients with non-biopsy-proven CHB who underwent LSM between May

2005 and December 2007 were enrolled in this prospective study. After LSM was

performed, patients attended regular follow-up as part of a surveillance program

for the detection of HCC. The mean age of the patients (767 men, 363 women) was

50.2 years, and the median LSM was 7.7 kPa. Six hundred seventy-two (59.5%)

patients received antiviral treatment before or after enrollment. During the

follow-up period (median, 30.7 months; range, 24.0-50.9 months), HCC developed

in 57 patients (2.0% per 1 person-year). The 1-, 2-, and 3-year cumulative

incidence rates of HCC were 0.80%, 3.26%, and 5.98%, respectively. On

multivariate analysis, together with old age, male sex, heavy alcohol

consumption (>80 g/day), serum albumin, and hepatitis B e antigen positivity,

patients with a higher LSM (>8 kPa) were at a significantly greater risk of HCC

development, with the following hazard ratios: 3.07 (95% confidence interval

[CI], 1.01-9.31; P = 0.047) for LSM 8.1-13 kPa; 4.68 (95% CI, 1.40-15.64; P =

0.012) for LSM 13.1-18 kPa; 5.55 (95% CI, 1.53-20.04; P = 0.009) for LSM 18.1-23

kPa; and 6.60 (95% CI, 1.83-23.84; P = 0.004) for LSM >23 kPa. Conclusion: Our

data suggest that LSM could be a useful predictor of HCC development in patients

with CHB.

(HEPATOLOGY 2011).

American Association for the Study of Liver Diseases.

PMID: 21319193 [PubMed - as supplied by publisher